Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.61 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 5/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893688 | 0.91 | MDM2 (0.75) | MDM2TP53POLBMAPTGRM5 | |
| SCHEMBL1436802 | 0.87 | MDM2 (0.48) | MDM2JAK2JAK1MAPTCNR2 | |
| SCHEMBL9894878 | 0.87 | MDM2 (0.58) | MDM2JAK2MAPT | |
| SCHEMBL9893748 | 0.87 | MDM2 (0.57) | MDM2GRM5CNR2PDE4BPDE4D | |
| SCHEMBL9894396 | 0.86 | MDM2 (0.52) | MDM2IKBKBPTPN11PARP1TP53 | |
| SCHEMBL1438018 | 0.85 | MDM2 (0.83) | MDM2IKBKBJAK2JAK1PTPN11 | |
| SCHEMBL1437101 | 0.83 | MDM2 (0.82) | MDM2IKBKBJAK2JAK1PTPN11 | |
| SCHEMBL6951731 | 0.82 | MDM2 (0.71) | MDM2IKBKBJAK2JAK1PTPN11 | |
| SCHEMBL1436894 | 0.82 | MDM2 (0.40) | MDM2JAK2TP53MAPT | |
| SCHEMBL1437240 | 0.78 | MDM2 (0.59) | MDM2TP53POLBMAPTCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885IKBKB 770/4885JAK2 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.